Several studies have been conducted into to effectiveness of the newest class of drugs, tumor necrosis factor (TNF)-alpha blockers, in treating rheumatoid arthritis. But there have been no published studies comparing TNF-alpha blockers with the older class of drugs, known as disease-modifying anti-rheumatic drugs (DMARDS), such as Remicade (infliximab), Enbrel (etanercept), and Humira (adalimumab).
Recently a [...]
